Kavya Keerthana: The Platelet Count Everyone Calls ‘Reactive’ Until It Isn’t
Kavya Keerthana, Hematologist at Prime Health, shared a post on LinkedIn:
“Mild Thrombocytosis: The Platelet Count Everyone Calls ‘Reactive’ Until It Isn’t
A patient comes in for something unrelated.
The CBC shows platelets at 520. Someone writes ‘reactive, recheck in follow-up’ – and nobody ever does.
Mild thrombocytosis is not one entity.
It’s a spectrum – from a transient bump after infection or iron deficiency, to an early myeloproliferative process quietly raising thrombotic risk long before a diagnosis is made.
The decision point isn’t the number. It’s recognizing when ‘probably reactive’ stops being a safe assumption.
A practical escalation pathway for persistent mild thrombocytosis:
- Separate transient reactive triggers (infection, iron deficiency, post-splenectomy, post-op) from a pattern with no clear driver
- Know which findings should prompt molecular testing rather than a repeat CBC
- Understand when JAK2 V617F, CALR, and MPL testing is indicated — and when it isn’t yet
- Recognize that thrombosis risk can precede a confirmed clonal diagnosis, and should be assessed independently
Hard decision points:
- Single, explained rise (post-op, infection, iron deficiency) – recheck in 4–6 weeks. One value should never trigger molecular workup.
- Platelets more than 450 x 10⁹/L, persistent beyond 3 months, no reactive cause found – send MPN panel, examine for splenomegaly, check for iron deficiency as a masking factor.
- Any thrombocytosis with a prior thrombotic event, microvascular symptoms (erythromelalgia, visual disturbance, digital ischemia), or counts more than1000 x 10⁹/L – don’t wait for molecular results. Risk-stratify for cytoreduction and antiplatelet therapy now.
The number that gets flagged as an incidental finding is sometimes the first sign of something that needed action months earlier.”
Stay updated with Hemostasis Today.
-
Aug 16, 2026, 12:16Jeff Schaffnit: The Power of Community in Rare Blood Disorders
-
Aug 16, 2026, 12:03Fawaz AlOtaibi: Can AI Replace Contrast CTA for Vascular Screening?
-
Aug 16, 2026, 10:31Erhabor Osaro: Critical Issues to Consider During the Clinical Blood Transfusion Process
-
Aug 16, 2026, 10:14Juan Manuel Cisneros Carrasco: The Architects Behind the Blood Donation System
-
Aug 16, 2026, 10:06Honoring the Life and Legacy of Dr. Reed Pyeritz – GADA Canada
-
Aug 16, 2026, 09:51Javier Amador-Castañeda: When a 32 Percent Reduction Tells Only Part of the Story
-
Aug 16, 2026, 09:33Anıl Güneş: The Unseen Threat – How Global Climate Change Impacts Cardiovascular Health
-
Aug 16, 2026, 09:09Robert John Nesbitt: Can We Prevent Stroke Without Increasing Bleeding Risk
-
Aug 16, 2026, 06:19Dennis Wolf: Is ZEUS the End of Anti-Inflammatory Therapy in Atherosclerosis?